Safety, quality & regulatory

What we honestly know about KPV safety, and what we do not

FDA states it has not identified any human exposure data on drug products containing KPV by any route, and that it lacks important information about any safety issue KPV raises: the safety column is unmeasured rather than clean. KPV is not an FDA-approved product. Its regulatory paper trail is easy to misread, so this unit walks it slowly: KPV was added to the FDA's 503A category 2 compounding safety-risk group in the list updated September 29, 2023, and the list updated April 22, 2026 records it removed because the nomination was withdrawn by the nominator. The evaluation carried on anyway, and KPV went to the Pharmacy Compounding Advisory Committee on July 23, 2026, where the FDA's own briefing document concluded that a balancing of the criteria weighs against placing KPV on the 503A bulks list. The committee went the other way and, in the reporting, recommended by a narrow margin that KPV be added. That recommendation is advice, not a rule: the reporting says it is not binding and that adding a substance to the list still has to go through public rulemaking. Product quality is a separate risk, covered below as this course's own guidance.

This unit separates the reassuring parts from the genuine open questions, covers the US regulatory reality, and gives you a practical lens on sourcing red flags, all as education, not medical advice.